August 26, 2013 | Amgen agreed to acquire Onyx Pharmaceuticals on Sunday for $10.4 billion. Amgen tried to acquire the in June for $120/share, but was rejected. Yesterday's agreement was for $125/share. Onyx, based in South San Francisco, has a drug product designed to fight blood cancers. Los Angeles Times